211 related articles for article (PubMed ID: 27611088)
1. Pre-Vaccination Care-Seeking in Females Reporting Severe Adverse Reactions to HPV Vaccine. A Registry Based Case-Control Study.
Mølbak K; Hansen ND; Valentiner-Branth P
PLoS One; 2016; 11(9):e0162520. PubMed ID: 27611088
[TBL] [Abstract][Full Text] [Related]
2. Examining determinants for reporting suspected adverse events following HPV vaccination in Denmark.
Ulendorf Jacobsen S; Valentiner-Branth P; Mølbak K
Vaccine; 2018 Oct; 36(41):6158-6162. PubMed ID: 30201304
[TBL] [Abstract][Full Text] [Related]
3. Hospital contacts and diagnoses five years prior to HPV vaccination among females referred for suspected adverse vaccine effects: A Danish nationwide case-control study.
Krogsgaard LW; Bech BH; Plana-Ripoll O; Thomsen RW; Rytter D
Vaccine; 2019 Mar; 37(13):1763-1768. PubMed ID: 30803841
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
6. Infections in temporal proximity to HPV vaccination and adverse effects following vaccination in Denmark: A nationwide register-based cohort study and case-crossover analysis.
Krogsgaard LW; Petersen I; Plana-Ripoll O; Bech BH; Lützen TH; Thomsen RW; Rytter D
PLoS Med; 2021 Sep; 18(9):e1003768. PubMed ID: 34495975
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study.
Silverberg MJ; Leyden WA; Lam JO; Gregorich SE; Huchko MJ; Kulasingam S; Kuppermann M; Smith-McCune KK; Sawaya GF
Lancet Child Adolesc Health; 2018 Oct; 2(10):707-714. PubMed ID: 30236379
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
9. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
10. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
[TBL] [Abstract][Full Text] [Related]
11. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
[TBL] [Abstract][Full Text] [Related]
12. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland.
Skufca J; Ollgren J; Artama M; Ruokokoski E; Nohynek H; Palmu AA
Vaccine; 2018 Sep; 36(39):5926-5933. PubMed ID: 30115524
[TBL] [Abstract][Full Text] [Related]
13. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
14. Are unexplained adverse health events following HPV vaccination associated with infectious mononucleosis? - A Danish nationwide matched case-control study.
Krogsgaard LW; Helmuth IG; Bech BH; Plana-Ripoll O; Lützen TH; Vestergaard HT; Bjerre KD; Thomsen RW; Mølbak K; Rytter D
Vaccine; 2020 Jul; 38(35):5678-5684. PubMed ID: 32624249
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer.
Klosky JL; Favaro B; Peck KR; Simmons JL; Russell KM; Green DM; Hudson MM
J Cancer Surviv; 2016 Jun; 10(3):449-56. PubMed ID: 26572902
[TBL] [Abstract][Full Text] [Related]
16. On the contextual nature of vaccine safety monitoring: Adverse events reporting after HPV-vaccination in Denmark, 2015.
Schartau S; Heering Holt D; Lützen T; Rytter D; Mølbak K
Vaccine; 2019 May; 37(19):2580-2585. PubMed ID: 30967312
[TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
18. Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination.
Morimoto A; Ueda Y; Egawa-Takata T; Yagi A; Terai Y; Ohmichi M; Ichimura T; Sumi T; Murata H; Kanzaki H; Nakai H; Mandai M; Yoshino K; Fujita M; Kimura T; Saito J; Sobue T; Nishikawa N; Sekine M; Enomoto T; Horikoshi Y; Takagi T
Int J Clin Oncol; 2015 Jun; 20(3):549-55. PubMed ID: 25001869
[TBL] [Abstract][Full Text] [Related]
19. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
[TBL] [Abstract][Full Text] [Related]
20. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
